Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments

Background and Aim:  Even with the current most effective treatment regimens for Helicobacter pylori infection, a considerable number of patients will be resistant to eradication. The aim of the present study was to evaluate the H. pylori eradication rate in patients resistant to standard therapies...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2007-01, Vol.22 (1), p.60-63
Main Authors: González Carro, Pedro, Pérez Roldán, Francisco, De Pedro Esteban, Aurora, Legaz Huidobro, Maria L., Soto Fernández, Susana, Roncero Garcia Escribano, Oscar, Esteban López-Jamar, Jose M., Pedraza Martin, Carmen, Ruíz Carrillo, Francisco
Format: Article
Language:English
Subjects:
2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use
Adult
Aged
Aged, 80 and over
Amoxicillin - therapeutic use
Anti-Bacterial Agents - therapeutic use
Anti-Ulcer Agents - therapeutic use
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacterial diseases
Bacterial diseases of the digestive system and abdomen
Biological and medical sciences
Chi-Square Distribution
Drug Therapy, Combination
Female
Helicobacter Infections - drug therapy
Helicobacter pylori
Helicobacter pylori - drug effects
Human bacterial diseases
Humans
Infectious diseases
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
rescue therapy
rifabutin
Rifabutin - therapeutic use
Statistics, Nonparametric
Treatment Outcome
triple therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim:  Even with the current most effective treatment regimens for Helicobacter pylori infection, a considerable number of patients will be resistant to eradication. The aim of the present study was to evaluate the H. pylori eradication rate in patients resistant to standard therapies when treated with a triple therapy of pantoprazole, rifabutin and amoxicillin. Methods:  Ninety‐two consecutive patients diagnosed with H. pylori infection resistant to two previous treatment regimens were treated with pantoprazole, rifabutin and amoxicillin for 10 days. The persistence or eradication of H. pylori was determined by a 13C‐urea breath test performed 4 weeks after the treatment. Results:  Per protocol eradication was achieved in 62.2% of patients and the intention‐to‐treat eradication was 60.8%. Only two patients were excluded for adverse events related to the treatment. Conclusions:  The eradication rate is acceptable as a third‐line therapy, particularly in centers with high cure rate for first line therapy. Another important value of this study is the good tolerance for the treatment observed in our patients. It is possible that rifabutin‐based triple therapy may be of use in hospital centers that do not have disposable culture and susceptibility methods against H. pylori.
ISSN:0815-9319
1440-1746
DOI:10.1111/j.1440-1746.2006.04375.x